24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

NCT02182830 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Hypertension

Interventions

DRUG: Empagliflozin low dose
DRUG: placebo
DRUG: Empagliflozin high dose

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]